Genomics-guided pre-clinical development of cancer therapies
- 22 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Cancer
- Vol. 1 (5), 482-492
- https://doi.org/10.1038/s43018-020-0067-x
Abstract
Since the approval of trastuzumab for the treatment of breast cancers more than two decades ago, many clinically effective targeted anti-cancer therapies have been developed. Here we consider the evidence that supports genomics-guided drug development and review the concept of oncogene addiction, including recent findings that inform this therapeutic approach. We consider non-oncogene addiction and how this synthetic-lethal paradigm could expand the range of new therapies, particularly for currently undruggable cancers. We discuss how CRISPR-based genetic screening is enhancing the ability to identify new targets. We conclude by considering opportunities for expanding the scope and refining the use of precision cancer medicines.Funding Information
- Wellcome Trust (206194)
- EIF | Stand Up To Cancer (SU2CAACR-DT1213)
- Cancer Research UK (C44943/A22536)
- British Lung Foundation
- Open Targets
This publication has 201 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial CellsThe American Journal of Pathology, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- L‐asparaginase treatment in acute lymphoblastic leukemiaCancer, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002